Zika Virus Clinical Trials 2024

What are the top hospitals conducting zika virus research?

In the ongoing battle against the Zika virus, several hospitals have emerged as significant contributors in clinical trials. One such institution is the CenExel Research Centers of America located in Oakland Park. Although they currently have only one active trial for Zika virus, their commitment to finding solutions is evident from their very first recorded trial back in 2023. Similarly, Velocity Clinical Research in Meridian and AMR East Wichita, formerly known as Heartland Associates East Wichita, are actively engaged in a single zika virus trial each. Both hospitals' dedication to tackling this global health threat is commendable considering their early start with initial trials also beginning in 2023.

Further expanding on these efforts are AMR Lexington, formerly Central Kentucky Research Associates based out of Lexington and Alliance for Multispecialty Research (AMR) LLC situated in Kansas City. These hospitals are actively conducting one zika virus clinical trial each—showing that even small numbers can signify significant steps forward when it comes to combating emerging diseases like Zika.

While it may seem that progress appears modest with only one active trial at each hospital, it's important to recognize that every effort counts towards understanding and addressing this complex virus effectively. The united commitment of these institutions signifies a collaborative approach toward combating Zika—a relentless pursuit aimed at safeguarding public health worldwide.

Which are the best cities for zika virus clinical trials?

When it comes to zika virus clinical trials, several cities are at the forefront of research. Atlanta, Georgia leads with 2 active trials focusing on interventions like the INTERCEPT Blood System for Red Blood Cells and others. Additionally, Oakland Park in Florida, Meridian in Idaho, Wichita in Kansas, and Lexington in Kentucky each have 1 active trial investigating the efficacy of the Purified Inactivated Zika Virus Vaccine (PIZV) and other potential treatments. These cities offer individuals affected by zika virus opportunities to participate in vital clinical trials that contribute to our understanding of this infectious disease and aid in developing effective prevention strategies moving forward.

Which are the top treatments for zika virus being explored in clinical trials?

In the realm of clinical trials, researchers are currently investigating a range of potential treatments for Zika virus. Leading the charge is the purified inactivated Zika Virus Vaccine (PIZV), which has one active trial and was first listed in 2023. Another promising contender is ZIKV-SJRP/2016-184 Strain, also with one ongoing trial and initially listed in 2022. Additionally, mRNA-1893 shows promise as a treatment option, with one active trial and two all-time trials since its introduction in 2019. These innovative approaches hold great potential to combat the challenges posed by Zika virus infection.

What are the most recent clinical trials for zika virus?

In the ongoing battle against the Zika virus, recent clinical trials offer promising advancements in our understanding and potential treatment options. One such trial focuses on evaluating the ZIKV-SJRP/2016-184 strain's effectiveness against this infectious disease. Additionally, mRNA-1893 is being investigated in a Phase 2 study to assess its efficacy as a possible intervention for Zika virus infection. Another significant development is the Phase 3 trial of the INTERCEPT Blood System, which aims to enhance safety by reducing zika transmission through red blood cell transfusions. These trials represent crucial steps forward in combating Zika virus and provide hope for improved prevention and management strategies moving forward.

What zika virus clinical trials were recently completed?

Recently completed clinical trials have provided valuable insights into the fight against the Zika virus. Notably, a trial sponsored by Inovio Pharmaceuticals was successfully completed in August 2021, evaluating their DNA-based vaccine candidate INO-A002. Another significant milestone in Zika research was reached when Themis Bioscience concluded their trial for MV-ZIKA-RV, an investigational live attenuated vaccine. These recent advancements signify important progress in our understanding of the Zika virus and bring us closer to developing effective preventive measures against this global health concern.